This symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.
Monday, June 4, 2018
Lunch & Registration
12:45 PM – 1:00 PM
CME Symposium / Q&A Session
1:00 PM – 2:15 PM
Grand Ballroom A/B/C
1400 6th Avenue
|12:45 PM – 1:00 PM
||Lunch and Registration
|1:00 PM – 1:10 PM
||Welcome and Introductions
||Camille Nelson Kotton, MD, FIDSA, FAST
|1:10 PM – 1:35 PM
||CMV: New Data and Challenging Clinical Case
||Deepali Kumar, MD, MSc, FRCP(C), FAST
|1:35 PM – 2:00 PM
||AMR: New Data and Challenging Clinical Case
||Alexandre Loupy, MD, PhD
|2:00 PM – 2:15 PM
||Panel Discussion with Audience Q&A Session
Camille Nelson Kotton, MD, FIDSA, FAST (Chair)
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Past Chair, Infectious Disease Community of Practice, American Society of Transplantation
Boston, Massachusetts (USA)
Alexandre Loupy, MD, PhD
Professor of Nephrology and Epidemiology
Department of Nephrology and Kidney Transplantation
H˘pital Necker / INSERM U970
Paris, France (Europe)
Deepali Kumar, MD, MSc, FRCP(C), FAST
Associate Professor of Medicine
Transplant Infectious Diseases & Multi Organ Transplant Program
University Health Network
Toronto, Ontario (Canada)
This activity has been designed to meet the educational needs of healthcare providers who manage cytomegalovirus (CMV) infection and/or antibody-mediated rejection (AMR) in patients who
After participating in this educational activity participants should be better able to:
- Implement prophylactic and preventive anti-CMV therapy in at-risk transplant patients as recommended by the current evidence base
- Promptly diagnose transplant patients with CMV infection and disease, using new and emerging assays and tools
- Apply clinical trial data for new and emerging treatment options to manage transplant patients infected with CMV, including those with resistant or refractory disease
- Select appropriate therapeutic agents using evidence-based protocols to prevent and treat AMR based on the pathophysiological underpinnings of the disease
- Integrate an understanding of the contribution of human leukocyte antigen (HLA) antibodies and complement deposition in transplant glomerulopathy (TG) and graft loss into the management of AMR
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and RMEI Medical Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a pharmaceutical, product, or device company. Any presenter, whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity, will not be permitted to present.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Albert Einstein College of Medicine, CCME staff, has no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity.
There is no fee for this educational activity.
This activity is jointly provided by RMEI Medical Education, LLC, Albert Einstein College of Medicine, and Montefiore Medical Center.
This activity is supported by independent medical educational grants from Merck and Shire.